H3K9me3
H3K9me3 has been well characterised as a mark of transcriptional repression. However, a study does suggest that it is also present at differentially expressed genes in cancers (PMID: 17968314). Reports suggest the presence of this site at silent as well as transcribed regions of the genome (PMID: 16061184). H3K9me3 is also important for transcriptional elongation of MHC II HLA-DRA genes (PMID: 17478518).
Download table as Excel
| Modified variants | Histone H3.1, Histone H3.2, Histone H3.3 |
|---|---|
| Writer/s | Histone-lysine N-methyltransferase SETDB1, Histone-lysine N-methyltransferase SETDB2, Histone-lysine N-methyltransferase SUV39H1, Histone-lysine N-methyltransferase SUV39H2 |
| Eraser/s | Lysine-specific demethylase 4A, Lysine-specific demethylase 4B, Lysine-specific demethylase 4C, Lysine-specific demethylase 4D |
| Disease associations | Metabolic disorder: Diabetes; PMID: 18579779 Neurological disorders: Fragile X syndrome; PMID: 20843831 Cancer: Acute myeloid leukaemia; PMID: 20498303 Pulmonary disorder: Idiopathic pulmonary fibrosis; PMID: 20404089 Muscle dystropy: Facioscapulohumeral dystrophy (FSHD); PMID: 19593370 Cancer: Melanoma; PMID: 21430779 Cancer: Chronic lymphocytic leukemia (CLL); PMID: 21062507 Neurological disorder: Huntington's disease; PMID: 17403718 Cancer: Acute myeloid leukaemia; PMID: 16861263 Cancer: Prostate cancer; PMID: 19739128 |
Sites of lysine methylation H1K186me1, H1K25me1, H2BK5me1, H3K27me1, H3K27me2, H3K27me3, H3K36me1, H3K36me2, H3K36me3, H3K4me1, H3K4me2, H3K4me3, H3K79me1, H3K79me2, H3K79me3, H3K9me1, H3K9me2, H3K9me3, H4K20me1, H4K20me2, H4K20me3